Oversubscribed Funding Round to Support US Registration Trial and ADHD Expansion
Blinklab (BB1: $0.32) has successfully raised $7.7 million in a heavily oversubscribed funding round, according to chairman Brian Leedman. The funds will be allocated towards its ongoing US registration trial for autism in children, as well as to expand the application of its technology to diagnosing Attention Deficit Hyperactivity Disorder (ADHD).
Financial Update and Expanded Market Opportunity
The company finished last month with a cash balance of $3.1 million. The expansion into ADHD not only broadens Blinklab’s total addressable market but also provides an important diagnostic tool for clinicians, as distinguishing between autism and ADHD in children can often be challenging.
US Autism Registration Study
In March, Blinklab initiated the lead-in phase for its US autism diagnosis registration study, which will initially assess 100 children. By the end of last month, 91 children had been enrolled. Data from these early patients is expected in the September quarter. Following this, the company will progress into the full registration study, which may involve 750 to 900 participants.
FDA Submission and ADHD Study Progress
Blinklab expects to submit its autism-related FDA dossier for marketing approval in early 2026. Additionally, the company is running an ongoing ADHD study, which has tested 200 children, with results expected in the current quarter.
Company Capitalisation and Future Prospects
Blinklab is currently capitalised at $40 million.
Bioshares Recommendation: Speculative Buy Class B
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
